Advanced in Menopause

Sabine C. Linn

Amsterdam, NH, NL 
Advanced in Menopause
Amsterdam, NH, NL 
OverviewLocationsClinical Research

Overview

Sabine Linn practices in Amsterdam, Netherlands. Ms. Linn is rated as an Advanced expert by MediFind in the treatment of Menopause. Her top areas of expertise are Breast Cancer, Triple-Negative Breast Cancer, BRCA Positive Breast Cancer, Mastectomy, and Salpingo-Oophorectomy.

Her clinical research consists of co-authoring 443 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 27 articles in the study of Menopause.

Gender
Female

Locations

Amsterdam, NH, Netherlands
Other Locations
Utrecht, UT, Netherlands
Netherlands
Noord, NB, Netherlands

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer Patients with Personalized Therapy (SUBITO) - an International Randomized Phase III Trial
Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer Patients with Personalized Therapy (SUBITO) - an International Randomized Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: November 20, 2024
Intervention Type: Drug
Study Drugs: ddAC-CP-Olaparib, ddAC-mini CTC
Study Phase: Phase 3
Biomarker Discovery Randomized Phase IIb Trial With Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer
Biomarker Discovery Randomized Phase IIb Trial With Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 21, 2024
Intervention Type: Drug
Study Drugs: Carboplatin, Cyclophosphamide, atezolizumab, Paclitaxel
Study Phase: Phase 2
Phase I/Prospective Randomized Phase II Trial Of the Safety and Efficacy of Tamoxifen in Combination With GDC-0032 Compared With Tamoxifen alONe.
Phase I/Prospective Randomized Phase II Trial Of the Safety and Efficacy of Tamoxifen in Combination With GDC-0032 Compared With Tamoxifen alONe.
Enrollment Status: Completed
Publish Date: October 12, 2022
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Feasibility Study of Niraparib for Advanced, BRCA1-like, HER2-negative Breast Cancer Patients: the ABC Study
A Feasibility Study of Niraparib for Advanced, BRCA1-like, HER2-negative Breast Cancer Patients: the ABC Study
Enrollment Status: Terminated
Publish Date: July 18, 2022
Intervention Type: Drug
Study Drug: Niraparib
Study Phase: Phase 2
A Phase 1b to Assess the Safety and Tolerability of Carboplatin-cyclophosphamide Combined With Atezolizumab, an Antibody That Targets Programmed Death Ligand 1 (PD-L1), in Patients With Advanced Breast Cancer and Gynaecologic Cancer
A Phase 1b to Assess the Safety and Tolerability of Carboplatin-cyclophosphamide Combined With Atezolizumab, an Antibody That Targets Programmed Death Ligand 1 (PD-L1), in Patients With Advanced Breast Cancer and Gynaecologic Cancer
Enrollment Status: Completed
Publish Date: October 19, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Randomized, Prospective Trial of 2-6 Weeks Pre-operative Hormonal Treatment for Hormone Receptor Positive Breast Cancer: Anastrozole +/- Fulvestrant or Tamoxifen Exposure - Response in Molecular Profile (AFTER-study).
A Randomized, Prospective Trial of 2-6 Weeks Pre-operative Hormonal Treatment for Hormone Receptor Positive Breast Cancer: Anastrozole +/- Fulvestrant or Tamoxifen Exposure - Response in Molecular Profile (AFTER-study).
Enrollment Status: Suspended
Publish Date: January 22, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 5 Less Clinical Trials

442 Total Publications

Brain imaging screening in metastatic breast cancer: patients' and physicians' perspectives.
Brain imaging screening in metastatic breast cancer: patients' and physicians' perspectives.
Journal: Breast (Edinburgh, Scotland)
Published: August 07, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Linn's expertise for a condition
ConditionClose
View All 12 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile